Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew W Johnson

Showing results (1-10 of 176) with videos related to

Pageof 18
Sort By:
Current Topics in Behavioral Neurosciences|June 15, 2022
Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking CessationMatthew W Johnson
International Review of Psychiatry (Abingdon, England)|July 9, 2019
Psychiatry might need some psychedelic therapyMatthew W Johnson
ACS Pharmacology & Translational Science|April 16, 2021
Consciousness, Religion, and Gurus: Pitfalls of Psychedelic MedicineMatthew W Johnson
Preventive Medicine|July 2, 2026
Behavioral economic demand analysis: A multidimensional framework for understanding drug reinforcement and tobacco scienceMatthew W Johnson
Experimental and Clinical Psychopharmacology|February 15, 2012
An efficient operant choice procedure for assessing delay discounting in humans: initial validation in cocaine-dependent and control individualsMatthew W Johnson
The British Journal of Psychiatry : the Journal of Mental Science|January 7, 2015
Can psychedelic compounds play a part in drug dependence therapy?Ben Sessa, Matthew W Johnson
Pharmacopsychiatry|December 7, 2020
Psychedelics and PsychotherapySandeep Nayak, Matthew W Johnson
Advances in Pharmacology (San Diego, Calif.)|March 28, 2022
Human behavioral pharmacology of psychedelicsJustin C Strickland, Matthew W Johnson
The Journal of Clinical Psychiatry|December 13, 2005
Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compoundsRoland R Griffiths, Matthew W Johnson
Experimental and Clinical Psychopharmacology|February 21, 2013
Comparative abuse liability of GHB and ethanol in humansMatthew W Johnson, Roland R Griffiths
Pageof 18

Showing results (1-10 of 176) with videos related to

Sort By:
Pageof 18
Current Topics in Behavioral Neurosciences|June 15, 2022
Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking CessationMatthew W Johnson
International Review of Psychiatry (Abingdon, England)|July 9, 2019
Psychiatry might need some psychedelic therapyMatthew W Johnson
ACS Pharmacology & Translational Science|April 16, 2021
Consciousness, Religion, and Gurus: Pitfalls of Psychedelic MedicineMatthew W Johnson
Preventive Medicine|July 2, 2026
Behavioral economic demand analysis: A multidimensional framework for understanding drug reinforcement and tobacco scienceMatthew W Johnson
Experimental and Clinical Psychopharmacology|February 15, 2012
An efficient operant choice procedure for assessing delay discounting in humans: initial validation in cocaine-dependent and control individualsMatthew W Johnson
The British Journal of Psychiatry : the Journal of Mental Science|January 7, 2015
Can psychedelic compounds play a part in drug dependence therapy?Ben Sessa, Matthew W Johnson
Pharmacopsychiatry|December 7, 2020
Psychedelics and PsychotherapySandeep Nayak, Matthew W Johnson
Advances in Pharmacology (San Diego, Calif.)|March 28, 2022
Human behavioral pharmacology of psychedelicsJustin C Strickland, Matthew W Johnson
The Journal of Clinical Psychiatry|December 13, 2005
Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compoundsRoland R Griffiths, Matthew W Johnson
Experimental and Clinical Psychopharmacology|February 21, 2013
Comparative abuse liability of GHB and ethanol in humansMatthew W Johnson, Roland R Griffiths
Pageof 18